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Abstract
Background: The Surgery As Needed for Oesophageal cancer (SANO) trial compares active surveillance with standard
oesophagectomy for patients with a clinically complete response (cCR) to neoadjuvant chemoradiotherapy. The last
patient with a clinically complete response is expected to be included in May 2021. The purpose of this update is to
present all amendments to the SANO trial protocol as approved by the Institutional Research Board (IRB) before accrual
is completed.
Design: The SANO trial protocol has been published (https://doi.org/10.1186/s12885-018-4034-1). In this ongoing,
phase-III, non-inferiority, stepped-wedge, cluster randomised controlled trial, patients with cCR (i.e. after neoadjuvant
chemoradiotherapy no evidence of residual disease in two consecutive clinical response evaluations [CREs]) undergo
either active surveillance or standard oesophagectomy. In the active surveillance arm, CREs are repeated every 3
months in the first year, every 4 months in the second year, every 6 months in the third year, and yearly in the fourth
and fifth year. In this arm, oesophagectomy is offered only to patients in whom locoregional regrowth is highly
suspected or proven, without distant metastases. The primary endpoint is overall survival.
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Update: Amendments to the study design involve the first cluster in the stepped-wedge design being partially randomised
as well and continued accrual of patients at baseline until the predetermined number of patients with cCR is reached.
Eligibility criteria have been amended, stating that patients who underwent endoscopic treatment prior to neoadjuvant
chemoradiotherapy cannot be included and that patients who have highly suspected residual tumour without histological
proof can be included. Amendments to the study procedures include that patients proceed to the second CRE if at the first
CRE the outcome of the pathological assessment is uncertain and that patients with a non-passable stenosis at endoscopy
are not considered cCR. The sample size was recalculated following new insights on response rates (34% instead of 50%)
and survival (expected 2-year overall survival of 75% calculated from the moment of reaching cCR instead of 3-year overall
survival of 67% calculated from diagnosis). This reduced the number of required patients with cCR from 264 to 224, but
increased the required inclusions from 480 to approximately 740 patients at baseline.
Conclusion: Substantial amendments were made prior to closure of enrolment of the SANO trial. These amendments do
not affect the outcomes of the trial compared to the original protocol. The first results are expected late 2023. If active
surveillance plus surgery as needed after neoadjuvant chemoradiotherapy for oesophageal cancer leads to non-inferior
overall survival compared to standard oesophagectomy, active surveillance can be implemented as a standard of care.
Keywords: Oesophageal cancer, Neoadjuvant chemoradiotherapy, Active surveillance, Standard oesophagectomy
Introduction
The Surgery As Needed for Oesophageal cancer (SANO)
trial is an ongoing phase-III trial that compares active sur-
veillance with standard oesophagectomy for patients with
a clinically complete response (cCR; i.e. no evidence of re-
sidual disease on diagnostics) to neoadjuvant chemoradio-
therapy for oesophageal or oesophagogastric junctional
cancer [1]. The trial is designed as a non-inferiority,
multi-centre, stepped-wedge, cluster randomised con-
trolled trial. The primary aim is to assess the effectiveness
of active surveillance compared to standard
oesophagectomy.
Patients are recruited from 12 high-volume centres in
the Netherlands. After completion of neoadjuvant che-
moradiotherapy (CROSS regimen) [2], two clinical re-
sponse evaluations (CREs) are performed: the first (CRE-
1) at 4–6 weeks and the second (CRE-2) at 10–14 weeks
after completion of neoadjuvant chemoradiotherapy.
CRE-1 consists of endoscopy with bite-on-bite biopsies
and CRE-2 consists of 18F-FDG PET/CT, followed by
endoscopy with bite-on-bite biopsies and endoscopic
ultrasonography (EUS) with fine-needle aspiration of
suspected lymph nodes. If a patient has cCR at CRE-2,
the patient will be assigned to either standard oesopha-
gectomy or active surveillance, depending on which
study arm the participating hospital was recruiting for
(according to the stepped-wedge, cluster randomised de-
sign) [1]. If locoregional residual or distant disease is de-
tected during one of these CREs, the patient is excluded
from further follow-up within the study.
Patients in the active surveillance arm undergo diag-
nostic evaluations similar to CRE-2 every 3 months in
the first year, every 4 months in the second year, every 6
months in the third year, and yearly in the fourth and
fifth year. During active surveillance, oesophagectomy
will be offered only to patients in whom locoregional re-
growth is highly suspected or proven in the absence of
distant metastasis. A schematic overview of the SANO
trial is provided in Fig. 1.
Ethical approval for the study has been obtained from
the institutional review board (IRB) of the Erasmus MC
(MEC2017–392). The trial has been registered in the
Netherlands Trial Register (NTR 6803) and is being con-
ducted in accordance with the Declaration of Helsinki
(10th version, Fortaleza, 2013) and the Dutch Medical
Research Involving Human Subjects Act (WMO).
The original SANO trial protocol has been published
in BMC Cancer in 2018 (https://doi.org/10.1186/s12885-
018-4034-1) [1]. Patient accrual has been started in No-
vember 2017, and the last patient with a clinically
complete response is expected to be included in May
2021. Following the publication of the protocol and start
of the trial, amendments have been made to the protocol
to reflect new insights about the accuracy of the CREs
and survival of the study population and to further clar-
ify the protocol regarding study procedures. The amend-
ments to the protocol have been approved by the IRB of
the Erasmus MC. The purpose of this update is to
present all amendments to the SANO trial protocol be-
fore accrual will be completed.
Study design
Two amendments have been made to the study design.
According to the stepped-wedge cluster randomised
trial design, clusters of centres are randomised from the
control arm to the experimental study arm. The initial
trial protocol stated that the centres in the first cluster
would not be randomly determined, but would consist
of Erasmus Medical Centre (coordinating centre and
sponsor of the trial) and Zuyderland Medical Centre.
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Both centres have extensive experience in performing
CREs and included a large number of patients in the
preSANO trial, ensuring maximal safety for introduction
of the novel active surveillance strategy [3]. Meanwhile,
there was another centre that gained extensive experi-
ence within the preSANO trial. To provide a random ef-
fect to this first cluster but ensure optimal patient safety,
we randomly assigned either Zuyderland Medical Centre
or Catharina Hospital to the first cluster together with
the Erasmus MC.
Since the cCR rate and the rate of crossover is variable
(see the “Statistical analysis” section), it is not possible to
determine an exact number of patients that need to be
included at baseline to end up with exactly the correct
number of patients with cCR. Therefore, to ensure that
we do not end up with a sample size that is too small
and thus an underpowered trial, we will continue includ-
ing patients at baseline until we reach the predetermined
number of patients with cCR. As a result, some patients
will be included at baseline but will not have reached the
moment of cCR yet, while the baseline enrolment of the
trial will be stopped. These additional patients will be in-
cluded in the analysis of the trial to increase the statis-
tical power.
Study population
Three amendments have been made to the eligibility
criteria.
First, a new exclusion criterion has been added to the
protocol to exclude patients who have had diagnostic or
therapeutic endoscopic treatment (e.g. endoscopic muco-
sal resection or endoscopic submucosal dissection) before
the start of neoadjuvant chemoradiotherapy. According to
the eligibility criteria of the initial protocol, these patients
could have been included in the trial at this moment.
However, since the oesophageal tumour, and especially
the luminal side of the tumour, has been largely removed
by the endoscopic resection, accurate detection of locore-
gional residual disease by means of endoscopic bite-on-
bite biopsies and follow-up with PET/CT might be ham-
pered. These patients are probably at increased risk of
having undetected residual disease during the CREs and
are thus possibly at increased risk of developing a non-
resectable regrowth.
Second, a small number of patients could not decide
to participate in the SANO trial before chemoradiother-
apy was started. Since the first CRE is not planned until
4–6 weeks after completion of chemoradiotherapy, the
trial protocol was amended to allow patients to be
Fig. 1 Schematic overview of the SANO trial, comparing active surveillance with standard oesophagectomy in patients with oesophageal cancer
and a clinically complete response after neoadjuvant chemoradiotherapy. Patients in whom no residual tumour is detected at two clinical
response evaluations after neoadjuvant chemoradiotherapy are considered to have a clinically complete response. Patients who do not have a
clinically complete response will undergo oesophagectomy in case no distant metastases are detected. If patients have residual disease at one of
the clinical response evaluations during active surveillance (CRE 3–12), postponed oesophagectomy will be performed in case no distant
metastases are detected and active surveillance will be stopped. nCRT neoadjuvant chemoradiotherapy, CRE clinical response evaluation, cCR
clinically complete responder
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included during or shortly after completion of chemora-
diotherapy. This might result in some missing baseline
health-related quality of life questionnaires.
Third, the initial trial protocol dictated that patients with
histologically proven squamous cell carcinoma or adenocar-
cinoma are eligible. An amendment was made that whenever
pathology is inconclusive but a multidisciplinary tumour
board concludes that there are sufficient (clinical) arguments
for the diagnosis of oesophageal carcinoma (e.g. because of a
radiologically, endoscopically, and/or endosonographically
highly suspected lesion) and subsequent treatment is neoad-
juvant chemoradiotherapy followed by surgery, patients are
eligible for the study as well. This situation occurs, however,
very rarely. An example of such a situation is as follows: a pa-
tient who is known with a history of Barrett’s oesophagus
presents with increasing dysphagia and weight loss. Endos-
copy shows a tumorous lesion within the Barrett segment in
the distal oesophagus, of which biopsies are taken. Endo-
scopic ultrasonography shows a cT3 tumour without positive
lymph nodes. The PET/CT scan shows an intense FDG-avid
lesion in the distal oesophagus without positive lymph nodes
and no distant metastases. The diagnostic CT scan also
shows a distal oesophageal tumour without nodal and distant
metastases. Eventually, pathology of the biopsies shows high-
grade dysplasia, with suspicion of but unconfirmed invasive
carcinoma. Despite the absence of confirmation of invasive
carcinoma, the patient is enrolled in the SANO trial and neo-
adjuvant chemoradiotherapy is started.
Study algorithm
Four amendments have been made to the study
algorithm.
First, the targeting of endoscopic biopsies can be hin-
dered and the pathological assessment of residual
tumour cells in the biopsy specimen at CRE-1 can be
unreliable due to radiation effects and inflammation. To
avoid a high rate of false positives at CRE-1 and since it
is known that surgery can be safely postponed up to 10–
14 weeks after completion of chemoradiotherapy, pa-
tients proceed to CRE-2 if the outcome of the patho-
logical assessment is uncertain at CRE-1 [4, 5]. Of note,
if patients have uncertain outcome of the pathological
assessment of the biopsy specimen at CRE-2, patients
will not be allowed to continue in the trial and will
undergo surgery, as information on the safety of further
postponement of surgery is lacking.
Second, the initial trial protocol described that at CRE-
2, patients with (cyto) histological evidence of locoregional
residual disease or highly suspected locoregional residual
disease on PET/CT without distant metastases will
undergo surgery, whereas patients without (cyto) histo-
logical evidence of residual disease are considered cCR.
We clarified the protocol and stated that patients who
have suspected lymph nodes on EUS which are
unreachable with fine-needle aspiration are not considered
cCR. If in the short term no representative cytology can
be obtained from suspected lymph nodes during CRE-2,
the patient will also not be considered cCR.
Third, the accuracy of endoscopic bite-on-bite biopsies
is compromised if a smaller biopsy instrument is being
used, for instance a paediatric endoscope. For this reason,
we amended the protocol to state that patients who have a
stenosis which cannot be passed with a normal Q-
endoscope during endoscopy at CRE-1 or CRE-2 will not
be considered cCR, regardless of traversability with the
paediatric endoscope. Comparably, in patients who have a
stenosis that cannot be passed with the ultrasound endo-
scope during CRE-II, an ultrasonographic assessment of
lymph nodes cannot be performed beyond the stenosis,
compromising complete assessment of the regional lymph
nodes. Therefore, patients with a non-passable stenosis
during EUS will not be considered cCR.
Fourth, the initial trial protocol dictated that CRE and
surveillance biopsies with uncertain outcome or with
high-grade dysplasia would have to be revised at the De-
partment of Pathology of the Erasmus MC. However,
often this is not logistically feasible, as for safety reasons
patients have to undergo surgery as soon as possible
after a positive biopsy. Therefore, the amendment states
that biopsies can be revised by a second independent ex-
pert GI pathologist in the participating centre following
the same strategy, using a standard protocol. In case of
discordant results, the specimens will be reviewed by a
third independent expert GI pathologist and a consensus
diagnosis should be reached if at least two pathologists
agree. In case the revision concludes high-grade dyspla-
sia, the CRE will be considered positive. In case the re-
sults remain uncertain, a multidisciplinary tumour board
at the Erasmus MC will reach consensus on further
treatment, taking into account the condition of the pa-
tient and other diagnostic modalities such as 18-FDG
PET-CT.
Follow-up
One amendment has been made to the follow-up of
patients.
To compare distant dissemination between both treat-
ment arms, the initial trial protocol described that pa-
tients included in the standard surgery arm have to
undergo PET-CT scans at 12 and 24 months after neo-
adjuvant chemoradiotherapy. However, the rationale for
the timing of these scans was a 12- and 24-month
follow-up period after surgery in the standard surgery
arm, which translates to a longer follow-up period when
calculated from completion of neoadjuvant chemoradio-
therapy. To reach sufficient follow-up time for the devel-
opment of metastases and thus make a fairer
comparison between the two study arms, the timing at
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which the follow-up PET/CT scans are planned in the
standard surgery arm has been changed from 12 and 24
months to 16 and 30months after neoadjuvant chemo-
radiotherapy. These points in time match the sixth and
ninth clinical response evaluations (CRE-6 and CRE-9)
in the active surveillance arm at which PET/CT scans
are also made. In this way, a distant dissemination rate
can be calculated at these exact points in time.
Study parameters/endpoints
No amendments have been made to the study parame-
ters/endpoints.
Safety and stopping rules
No amendments have been made to the safety and stop-
ping rules.
Statistical analysis
One amendment has been made to the statistical
analysis.
Initially, it was calculated that 264 patients with cCR
would be required to demonstrate that active surveil-
lance is non-inferior to standard surgery. For this sample
size calculation, an expected 3-year overall survival of
67%, non-inferiority margin of 15%, intra-centre correl-
ation coefficient of 0.02, power of 80%, and significance
level of 0.05 were used. These survival data were based
on the CROSS trial and defined from the moment of
randomisation (i.e. pre-treatment) [2, 6]. Based on pre-
liminary data of the preSANO trial, the initial sample
size calculation accounted for a 50% cCR rate and a 12%
drop-out rate (e.g. patients with cCR within the surgery
arm who request active surveillance arm, or vice versa;
so-called crossover patients). Moreover, to reduce the
number of newly included patients needed and to opti-
mally use the data from the preSANO trial, 60 patients
with cCR from the preSANO trial were expected to be
included in the SANO trial.
Based on the final data of the preSANO trial and mon-
itoring data of the first part of the SANO trial, it ap-
peared that the cCR rate was 34% and the crossover
percentage was 20%. Moreover, it appeared that only 29
instead of 60 patients with cCR from the preSANO trial
met all criteria of the SANO trial and could be included.
Also, new data on survival of patients with cCR after
neoadjuvant chemoradiotherapy have become available
[7]. Based on these data, the sample size has been recal-
culated. The sample size was recalculated with expected
2-year overall survival of 75%, defined from the moment
at which patients reach cCR (which is approximately 5
months after diagnosis). Accordingly, the sample size
was recalculated with the predetermined power of 80%,
significance level of 0.05, non-inferiority margin of 15%,
and intra-centre correlation coefficient of 0.02. As a
result, 224 patients (i.e. 112 patients in each arm) with
cCR will have to be enrolled in the trial. With a cross-
over rate of 20%, the total number of required inclusions
will be 280 (= 224/0.8) patients with cCR. Taking into
account that 29 patients with cCR can be included from
the preSANO trial and a cCR rate of 34%, this will trans-
late into approximately 740 patients required at baseline.
Simulating trial outcomes on 2-year overall survival cal-
culated from the moment of cCR (approximately 5months
after diagnosis) is justified compared to 3-year overall sur-
vival calculated from diagnosis, as the power and signifi-
cance levels are maintained and our primary endpoint will
remain overall survival. Two years is a commonly used
minimum follow-up time for comparable oncological trials,
which is expected to capture the most relevant data for the
short-term analysis. Moreover, the short-term results of the
trial and thus the potential implementation of active sur-
veillance as an alternative treatment strategy can be per-
formed a year earlier, avoiding the unnecessary delay of
providing organ sparing treatment for patients with locally
advanced oesophageal cancer. Importantly, long-term ana-
lyses will be performed after the last included patient fin-
ished the active surveillance protocol (minimum follow-up
of 5 years), as was previously defined.
Ethical and regulatory considerations
No amendments have been made to the ethical and
regulatory considerations.
Conclusion
In conclusion, substantial amendments were made prior
to closure of enrolment of the SANO trial. These
amendments do not affect the outcomes of the trial
compared to the original protocol. The last patient with
a clinically complete response is expected to be included
in May 2021. Guaranteeing a minimum follow-up of 2
years, the first results are expected late 2023.
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